AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3F0hyDG
via IFTTT